A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs are at different doses.

2023-508459-37-00 Protocol XO45189 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 28 May 2024 · Status Ongoing, recruitment ended · 3 EU/EEA countries · 25 sites · Protocol XO45189

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 114
Countries 3
Sites 25

HER2-positive advanced solid tumours

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
28 May 2024 → ongoing
Decision date (initial)
2024-04-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-508459-37-00
ClinicalTrials.gov
NCT05593094

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

HER2-positive advanced solid tumours

VersionLevelCodeTermSystem organ class
21.1 LLT 10072740 Locally advanced breast cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information Support Line-TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Head of EU

Locations

3 EU/EEA countries · 25 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 15 7
Italy Ongoing, recruitment ended 5 5
Spain Ongoing, recruitment ended 14 13
Rest of world
United Kingdom, Australia, New Zealand, United States
80

Investigational sites

France

7 sites · Ongoing, recruitment ended
Institut Paoli-Calmettes
N/A, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille
Centr Georges Francois Leclerc
N/A, 1 Rue Professeur Marion, 21000, Dijon
Centre Leon Berard
N/A, 28 Rue Laennec, 69008, Lyon
Institut Gustave Roussy
N/A, 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Oscar Lambret
N/A, 3 Rue Frederic Combemale, 59000, Lille
Institut Universitaire Du Cancer Toulouse-Oncopole
N/A, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Institut De Cancerologie De L Ouest
N/A, Bd Du Professeur Jacques Monod, 44800, St Herblain

Italy

5 sites · Ongoing, recruitment ended
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
Struttura Complessa di Oncologia, Piazza Oms 1, 24127, Bergamo
Fondazione IRCCS San Gerardo Dei Tintori
Centro Ricerca Fase 1, Via Giovanni Battista Pergolesi 33, 20900, Monza
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1 Unit, Largo Francesco Vito 1, 00168, Rome
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Struttura Complessa di Oncologia Medica, Via Piero Maroncelli 40, 47014, Meldola
Istituto Europeo Di Oncologia S.r.l.
New Drug Development for Innovative Therapies (Sviluppo di Nuovi Farmaci per Terapie Innovative), Via Giuseppe Ripamonti 435, 20141, Milan

Spain

13 sites · Ongoing, recruitment ended
Hospital Clinic De Barcelona
Medical Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Ramon Y Cajal
Medical Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitario 12 De Octubre
Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitari Dexeus Grupo Quironsalud
Medical Oncology, Calle De Sabino Arana 5-19, 08028, Barcelona
University Hospital Virgen Del Rocio S.L.
Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla
Fundacion Instituto Valenciano De Oncologia
Medical Oncology, Calle Professor Beltran Baguena 8, 46009, Valencia
Hospital Universitario De Jaen
Medical Oncology, Avenida Del Ejercito Espanol 10, 23007, Jaen
Hospital Universitari Vall D Hebron
Medical Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Universitario Virgen De La Macarena
Oncology, Avenida Del Doctor Fedriani 3, 41009, Sevilla
Hospital Clinico San Carlos
Oncology, Calle Del Profesor Martin Lagos Sn, 28040, Madrid
Hospital Beata Maria Ana
Oncology, Calle Del Doctor Esquerdo No. 83, 28007, Madrid
Complexo Hospitalario Universitario De Santiago
Medical Oncology, Calle Choupana Da S/n, 15706, Santiago De Compostela

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-06-13 2024-09-05 2025-07-30
Italy 2025-07-02 2025-07-28 2025-07-30
Spain 2024-05-28 2024-06-26 2025-07-08

Application history

9 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-15 France Acceptable
2024-04-22
2024-04-23
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-25 France Acceptable
2024-09-03
2024-09-04
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-11-18 France Acceptable
2024-09-03
2024-11-18
4 SUBSTANTIAL MODIFICATION SM-2 2024-11-25 Acceptable 2024-12-05
5 SUBSEQUENT ADDITION OF MSC APP-5 2025-02-24 2025-05-21
6 SUBSTANTIAL MODIFICATION SM-3 2025-06-27 France Acceptable
2025-09-12
2025-09-12
7 SUBSTANTIAL MODIFICATION SM-4 2025-10-09 France Acceptable
2025-10-24
2025-10-24
8 SUBSTANTIAL MODIFICATION SM-5 2025-11-04 France Acceptable
2025-11-26
2025-11-26
9 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-08 France Acceptable
2025-11-26
2025-12-08